REFERENCES
1. GBD 2023 Disease and Injury and Risk Factor Collaborators. Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023. Lancet. 2025;406:1873-922.
2. Gunnarsson S, Vito O, Unwin RJ. Cardiovascular-kidney-metabolic syndrome: prevalence, risks, disease trajectories, and early-stage management. Am J Physiol Cell Physiol. 2026;330:C1-8.
3. Bharaj IS, Brar A, Kacheria A, et al. Contemporary and emerging therapeutics in cardiovascular-kidney-metabolic (CKM) syndrome: in memory of Professor Akira Endo. Biomedicines. 2025;13:2192.
4. Ndumele CE, Neeland IJ, Tuttle KR, et al. ; American Heart Association. A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from The American Heart Association. Circulation. 2023;148:1636-64.
5. Shi P, Lou C, Fang J, Song Y. Adverse life events across the life course and the risk of new-onset cardiovascular-kidney-metabolic multimorbidity in middle-aged and older adults: longitudinal evidence from CHARLS. J Am Heart Assoc. 2025;14:e045192.
6. Shen C, Yang R, Zhou Y, et al. Metabolic dysfunction associated steatotic liver disease, cardiometabolic multimorbidity and mortality: evidence from the UK biobank. Clin Res Cardiol. 2026;115:1378-88.
7. Zhou Y, Dai X, Ni Y, et al. Interventions and management on multimorbidity: an overview of systematic reviews. Ageing Res Rev. 2023;87:101901.
8. Hall JE, do Carmo JM, da Silva AA, Wang Z, Hall ME. Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. Circ Res. 2015;116:991-1006.
9. Czaja-Stolc S, Potrykus M, Stankiewicz M, Kaska Ł, Małgorzewicz S. Pro-inflammatory profile of adipokines in obesity contributes to pathogenesis, nutritional disorders, and cardiovascular risk in chronic kidney disease. Nutrients. 2022;14:1457.
10. Sun X, Yan AF, Shi Z, et al. Health consequences of obesity and projected future obesity health burden in China. Obesity. 2022;30:1724-51.
11. Peng W, Chen S, Chen X, et al. Trends in major non-communicable diseases and related risk factors in China 2002-2019: an analysis of nationally representative survey data. Lancet Reg Health West Pac. 2024;43:100809.
12. Yan Z, Chang X, Liu Z, Liu R, Du X. The association of obesity and lipid-related indicators with all-cause and cardiovascular mortality risks in patients with diabetes or prediabetes: a cross-sectional study based on machine learning algorithms. Front Endocrinol. 2025;16:1492082.
13. Wang C, He S, Xie G, et al. Associations of longitudinal trajectories of triglyceride-glucose index combined with classical and novel obesity indices and cardiovascular disease: evidence from a nationwide prospective cohort study in China. Cardiovasc Diabetol. 2025;24:431.
14. Zhang H, Zhang Y, Gao W, Mu Y. Identification of risk factors and development of a predictive model for chronic kidney disease in patients with obesity: a four-year cohort study. Lipids Health Dis. 2024;23:57.
15. Jiang Y, Zhao B, Wang X, et al. UKB-MDRMF: a multi-disease risk and multimorbidity framework based on UK biobank data. Nat Commun. 2025;16:3767.
16. Huang Q, Zou X, Lian Z, et al. Predicting cardiovascular outcomes in Chinese patients with type 2 diabetes by combining risk factor trajectories and machine learning algorithm: a cohort study. Cardiovasc Diabetol. 2025;24:61.
17. Zhu J, Shi Z, Ge Z, et al. Comparative analysis of cardiometabolic multimorbidity predictors in China and the USA: a machine learning approach. Diabetes Res Clin Pract. 2025;229:112938.
18. Liu T, Krentz A, Lu L, Curcin V. Machine learning based prediction models for cardiovascular disease risk using electronic health records data: systematic review and meta-analysis. Eur Heart J Digit Health. 2025;6:7-22.
19. Xu D, Xu Z. Machine learning applications in preventive healthcare: a systematic literature review on predictive analytics of disease comorbidity from multiple perspectives. Artif Intell Med. 2024;156:102950.
20. Khalid F, Alsadoun L, Khilji F, et al. Predicting the progression of chronic kidney disease: a systematic review of artificial intelligence and machine learning approaches. Cureus. 2024;16:e60145.
21. Zhao Y, Hu Y, Smith JP, Strauss J, Yang G. Cohort profile: the China Health and Retirement Longitudinal Study (CHARLS). Int J Epidemiol. 2014;43:61-8.
22. Rubino F, Cummings DE, Eckel RH, et al. Definition and diagnostic criteria of clinical obesity. Lancet Diabetes Endocrinol. 2025;13:221-62.
23. Gao M, Lv J, Yu C, et al. ; China Kadoorie Biobank (CKB) Collaborative Group. Metabolically healthy obesity, transition to unhealthy metabolic status, and vascular disease in Chinese adults: a cohort study. PLoS Med. 2020;17:e1003351.
24. Zhou Y, Kivimäki M, Yan LL, et al. Associations between socioeconomic inequalities and progression to psychological and cognitive multimorbidities after onset of a physical condition: a multicohort study. EClinicalMedicine. 2024;74:102739.
25. Song Y, Zhu C, Shi B, et al. Social isolation, loneliness, and incident type 2 diabetes mellitus: results from two large prospective cohorts in Europe and East Asia and Mendelian randomization. EClinicalMedicine. 2023;64:102236.
26. Li X, Zhang W, Zhang W, et al. Level of physical activity among middle-aged and older Chinese people: evidence from the China health and retirement longitudinal study. BMC Public Health. 2020;20:1682.
27. Jiang C, Sun J, Lv Y, et al. The Chinese version of the 8-item Center for Epidemiologic Studies Depression Scale: Longitudinal psychometric syntheses with 10-year cohort multi-center evidence in an adult sample. Gen Hosp Psychiatry. 2024;91:204-11.
28. Zeng M, Chen Y, Lobanov-Rostovsky S, et al. Adiposity and dementia among Chinese adults: longitudinal study in the China Health and Retirement Longitudinal Study (CHARLS). Int J Obes. 2025;49:706-14.
29. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71:1269-324.
30. American Diabetes Association. 2. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018;41:S13-27.
31. Joint committee issued Chinese guideline for the management of dyslipidemia in adults. [2016 Chinese guideline for the management of dyslipidemia in adults]. Zhonghua Xin Xue Guan Bing Za Zhi. 2016;44:833-53.
32. Pavlou M, Omar RZ, Ambler G. Penalized regression methods with modified cross-validation and bootstrap tuning produce better prediction models. Biom J. 2024;66:e202300245.
33. Witte J, Foraita R, Didelez V. Multiple imputation and test-wise deletion for causal discovery with incomplete cohort data. Stat Med. 2022;41:4716-43.
34. Silva GFS, Fagundes TP, Teixeira BC, Chiavegatto Filho ADP. Machine learning for hypertension prediction: a systematic review. Curr Hypertens Rep. 2022;24:523-33.
35. Hu J, Szymczak S. A review on longitudinal data analysis with random forest. Brief Bioinform. 2023;24:bbad002.
36. Fu C, Zhang Z, Li Y, et al. Association of the estimated glucose disposal rate combined with a body shape index with all-cause and cardiovascular-specific mortality among individuals with cardiovascular-kidney-metabolic syndrome. Cardiovasc Diabetol. 2026;25:112.
37. Zhang X, Yao W, Wang D, Hu W, Zhang G, Zhang Y. Development and validation of machine learning models for identifying prediabetes and diabetes in normoglycemia. Diabetes Metab Res Rev. 2024;40:e70003.
38. Jia W, Liu X, Wang Y, Pedrycz W, Zhou J. Semisupervised learning via axiomatic fuzzy set theory and SVM. IEEE Trans Cybern. 2022;52:4661-74.
40. Nohara Y, Matsumoto K, Soejima H, Nakashima N. Explanation of machine learning models using shapley additive explanation and application for real data in hospital. Comput Methods Programs Biomed. 2022;214:106584.
41. Wang W, Liu Y, Yuan D, et al. Association between metabolic multimorbidity and the risk of cardiovascular disease, kidney disease, and mortality: longitudinal evidence from CHARLS (2011-2020). Public Health. 2025;249:106020.
42. Song G. The C-reactive protein-triglyceride glucose index (CTI) predicts mortality in cardiovascular-kidney-metabolic syndrome: a dual-cohort study with machine learning validation. Int J Surg. 2026;112:1340-52.
43. He D, Zhang X, Li C, et al. Rising prevalence of cardiovascular-kidney-metabolic syndrome in China, 2010-2019: national cross-sectional surveys. J Am Coll Cardiol. 2025;86:213-6.
44. Zhao W, Yan Q, Mou C. Physical activity and cardiovascular-metabolic disease risk across cardiovascular-kidney-metabolic syndrome stages: a population-based cohort study. BMC Cardiovasc Disord. 2025;25:748.
45. Choi S, Oh M, Lee DH, Jee SH, Jeon JY. Invasive and non-invasive variables prediction models for cardiovascular disease-specific mortality between machine learning vs. traditional statistics. Sci Rep. 2025;15:35093.
